Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. reported that Chief Executive Officer John C.M. Farquhar exercised stock options covering 31,220 shares of common stock on 2026-07-30. The options converted at exercise prices of $2.22, $8.33 and $9.58 per share. Footnotes describe vesting schedules with monthly installments continuing until July 1, 2027 and November 12, 2028 for certain grants, while another grant is already fully exercisable.
Heartflow, Inc. Chief Financial Officer Vikram Verghese exercised stock options for 22,522 shares of common stock on July 27, 2026 at $2.22 per share. He now holds 255,898 common shares directly and 66,588 stock options that vest monthly until October 30, 2027 and expire on December 24, 2033.
Heartflow, Inc. director Jeffrey C. Lightcap exercised stock options covering 47,420 shares of common stock on July 24, 2026 at an exercise price of $19.00 per share. Following the exercise, his directly held common stock position increased to 293,681 shares, and the reported option grant was fully exhausted.
Affiliated investment entities report additional Heartflow common stock holdings: 4,615,542 shares by HCPCIV 1, LLC, 833,075 shares by HealthCor Partners Fund II, L.P., and 1,248,939 shares by HealthCor Partners Fund, L.P. Lightcap may be deemed to share voting and dispositive power over these securities but disclaims beneficial ownership beyond his pecuniary interest.
BlackRock, Inc. reported a passive ownership stake in HeartFlow Inc. common stock. BlackRock and its specified business units beneficially own 4,934,928 shares, representing 5.7% of the outstanding common stock.
BlackRock has sole voting power over 4,834,585 shares and sole dispositive power over 4,934,928 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds from these shares, but no single person holds more than five percent of HeartFlow’s total outstanding common shares. The position is held through BlackRock’s subsidiaries and affiliates as described in an exhibit.
Heartflow, Inc. director Timothy C. Barabe exercised 3,710 stock options for Heartflow common stock on July 22, 2026 at an exercise price of $19.00 per share. The exercise converted the options into 3,710 shares of common stock, leaving him with 15,000 stock options and 188,231 common shares held directly.
Heartflow, Inc. reports that Chief Financial Officer Vikram Verghese exercised stock options for 22,522 shares of common stock at $2.22 per share on 2026-07-21. The stock option position decreased to 89,110 options, while his directly held common stock increased to 233,376 shares. The option vests in monthly installments through October 30, 2027, subject to continued service.
Heartflow, Inc. director Timothy C. Barabe exercised stock options covering 5,000 shares of common stock on July 17, 2026 at an exercise price of $19.00 per share. Following the option exercise, he directly owned 184,521 common shares and held 18,710 stock options, which are fully exercisable.
Heartflow Chief Medical Officer Campbell Rogers exercised 9,219 stock options at an exercise price of $19.00 per share into common stock on July 15, 2026, and on the same day sold 9,219 common shares at $25.72 per share pursuant to a Rule 10b5-1 Trading Plan adopted on December 12, 2025.
After these transactions, he held 88,731 Heartflow common shares directly and 92,191 stock options, and also had indirect common stock holdings through trusts, including 50,754, 26,012, 46,159 and 22,615 shares held by various Rogers family trusts.
Campbell D. Rogers has filed a notice to sell 9,219 shares of HTFL common stock on July 15, 2026 on NASDAQ. These shares were acquired the same day through a stock option exercise paid in cash. Over the prior three months, Rogers reported selling 9,219 common shares on May 18, 2026 for a total of 261266.46.
Heartflow, Inc. Chief Executive Officer and director Farquhar John C.M. reported an open-market sale of 22,562 shares of Common Stock on July 10, 2026 at a price of $27.75 per share. Following the transaction, he holds 435,373 shares directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.